While all biAbs are defined by their ability to bind two antigens, blinatumomab is a biAb that cross-links effector and target cells for cancer immunotherapy by engaging CD3 on T cells and CD19 on acute lymphoblastic leukemia cells. The gene discussed is CD19; the disease is cancer.